Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners is a fund dedicated to investing in publicly-held and privately-held healthcare companies.
Business Model:
Revenue: $2.4M
Employees: 11-50
Rankings
Industries / Tags:
Detailed Venrock Healthcare Capital Partners Information
Geographic Data
Address: 3340 Hillview Avenue
City: Palo Alto
State: CA
Zip: 94304
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Facebook
Twitter
Linkedin
Crunchbase
Metrics
5,474,218Website Global Rank
1,491Website Monthly Traffic
Twitter Followers
Description
Venrock Healthcare Capital Partners is a fund dedicated to investing in publicly-held and privately-held healthcare companies. It leverages its venture expertise, rigorous data analysis, and long-term supportive orientation to support successful biotechnology companies within the public markets. The company is headquartered in Palo Alto, California with an office in New York, New York.
Contact Phone:
+16505619580
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 9/2022 | Abivax | Post-IPO Equity | 0 |
| 4/2022 | Dianthus Therapeutics | Series A | 0 |
| 12/2021 | Mythic Therapeutics | Series B | 0 |
| 10/2020 | LianBio | Series A | 0 |
| 12/2020 | Cullinan Oncology | Series C | 131.2M |
| 1/2019 | Sojournix | Series C | 44M |
| 6/2023 | ORIC Pharmaceuticals | Post-IPO Equity | 0 |
| 11/2022 | Lusaris Therapeutics | Series A | 0 |
| 4/2022 | Lyra Therapeutics | Post-IPO Equity | 0 |
| 1/2022 | Apogee Therapeutics | Series A | 20M |
| 4/2021 | GH Research | Series B | 125M |
| 2/2018 | Kiniksa Pharmaceuticals | Series C | 200M |
| 8/2020 | Taysha Gene Therapies | Series B | 0 |
| 4/2022 | Trevi Therapeutics | Private Placement | 55M |
| 6/2018 | Metacrine | Series C | 65M |
| 12/2022 | Apogee Therapeutics | Series B | 0 |
| 6/2022 | DBV Technologies | Post-IPO Equity | 0 |
| 2/2021 | Artiva Biotherapeutics | Series B | 120M |
| 8/2020 | Kinnate Biopharma | Series C | 98M |
| 1/2019 | Attune Pharmaceuticals | Series B | 23M |
| 12/2020 | RayzeBio | Series B | 105M |
| 6/2020 | Athira Pharma | Series B | 85M |
| 10/2019 | Constellation Pharmaceuticals | Post-IPO Equity | 65M |
| 6/2023 | Upstream Bio | Series B | 0 |
| 5/2023 | Lyra Therapeutics | Post-IPO Equity | 0 |
| 5/2022 | Celcuity | Post-IPO Equity | 0 |
| 4/2020 | Devoted Health | Series C | 450M |
| 2/2021 | Centessa Pharmaceuticals | Series A | 250M |
| 4/2018 | Corvidia | Series B | 60M |
| 5/2021 | Nuvalent | Series B | 0 |
| 3/2021 | Graphite Bio | Series B | 150.7M |
| 6/2021 | RayzeBio | Series C | 108M |
| 2/2023 | Abivax | Post-IPO Equity | 0 |
| 7/2020 | Cogent Biosciences | Post-IPO Equity | 104.4M |
| 11/2021 | Ablaze Pharmaceuticals | Series A | 0 |
| 5/2023 | Carmot Therapeutics | Series E | 0 |
| 7/2022 | Annexon Biosciences | Post-IPO Equity | 0 |
| 8/2022 | Terns Pharmaceuticals | Post-IPO Equity | 0 |
| 10/2022 | VectivBio | Post-IPO Equity | 0 |
| 10/2018 | Milestone Pharmaceuticals | Series D | 80M |
| 3/2021 | Amunix | Series B | 117M |
| 5/2020 | Surface Oncology | Post-IPO Equity | 28.9M |
| 6/2023 | Upstream Bio | Series B | 0 |
| 5/2023 | Lyra Therapeutics | Post-IPO Equity | 0 |
| 5/2023 | Carmot Therapeutics | Series E | 0 |
| 2/2023 | Abivax | Post-IPO Equity | 0 |
| 12/2022 | Apogee Therapeutics | Series B | 0 |
| 11/2022 | Lusaris Therapeutics | Series A | 0 |
| 10/2022 | VectivBio | Post-IPO Equity | 0 |
| 9/2022 | Abivax | Post-IPO Equity | 0 |
| 8/2022 | Terns Pharmaceuticals | Post-IPO Equity | 0 |
| 7/2022 | Annexon Biosciences | Post-IPO Equity | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
